MicroRNA-Mediated In Vitro and In Vivo Direct Reprogramming of Cardiac Fibroblasts to Cardiomyocytes by Jayawardena, Tilanthi M. et al.
MicroRNA-mediated in vitro and in vivo Direct Reprogramming
of Cardiac Fibroblasts to Cardiomyocytes
Tilanthi M. Jayawardena, Ph.D.1,2, Bakytbek Egemnazarov, Ph.D.1,2, Elizabeth A. Finch,
Ph.D.1,3, Lunan Zhang, M.D.1,2, J. Alan Payne, B.A.1,2, Kumar Pandya, Ph.D.5, Zhiping
Zhang, M.D., Ph.D.1,2, Paul Rosenberg, M.D.1,3,4, Maria Mirotsou, Ph.D.1,2,*, and Victor J.
Dzau, M.D.1,2
1Duke Cardiovascular Research Center, Duke University Medical Center, Durham, NC
2Mandel Center for Hypertension and Atherosclerosis Research, Duke University Medical Center
Durham, NC
3Ion Channel Research Group, Duke University Medical Center, Durham, NC
4Sarah Steadman Nutrition and Metabolism Center, Duke University School of Medicine, Durham,
NC
5Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill,
Chapel Hill, NC
Abstract
Rationale—Repopulation of the injured heart with new, functional cardiomyocytes remains a
daunting challenge for cardiac regenerative medicine. An ideal therapeutic approach would
involve an effective method at achieving direct conversion of injured areas to functional tissue in
situ.
Objective—The aim of this study was to develop a strategy that identified and evaluated the
potential of specific miRNAs capable of inducing reprogramming of cardiac fibroblasts directly to
cardiomyocytes in vitro and in vivo.
Methods and Results—Using a combinatorial strategy, we identified a combination of
microRNAs (miRNA) 1, 133, 208, and 499 capable of inducing direct cellular reprogramming of
fibroblasts to cardiomyocyte-like cells in vitro. Detailed studies of the reprogrammed cells,
demonstrated that a single transient transfection of the microRNAs can direct a switch in cell fate
as documented by expression of mature cardiomyocyte markers, sarcomeric organization, and
exhibition of spontaneous calcium flux characteristic of a cardiomyocyte-like phenotype.
Interestingly, we also found that miRNA-mediated reprogramming was enhanced 10 fold upon
JAK inhibitor I treatment. Importantly, administration of microRNAs into ischemic mouse
myocardium resulted in evidence of direct conversion of cardiac fibroblasts to cardiomyocytes in
situ. Genetic tracing analysis using Fsp1Cre-traced fibroblasts from both cardiac and non-cardiac
cell sources strongly suggests that induced cells are most likely of fibroblastic origin.
Conclusion—The findings from this study provide the first proof-of-concept that miRNAs have
the capability of directly converting fibroblasts to a cardiomyocyte-like phenotype in vitro. Also
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of significance is that this is the first report of direct cardiac reprogramming in vivo. Our approach
may have broad and important implications for therapeutic tissue regeneration in general.
Keywords
Direct reprogramming; cardiac differentiation; microRNAs; tissue regeneration
INTRODUCTION
Response to cardiac injury is characterized by inadequate cardiomyocyte regeneration and
excessive fibrosis resulting in significant impairment of tissue structure and function.
Despite major developments in cardiac regenerative medicine, repopulation of the injured
heart with new, functional cardiomyocytes remains a daunting challenge. Recently,
landmark reports describing the reprogramming of somatic cells to induced pluripotent stem
(iPS) cells have raised the possibility of using cellular reprogramming for cardiac tissue
regeneration1, 2. These include directed cardiogenesis in vitro, of partially reprogrammed
fibroblasts3 as well as transplantation of the ischemic heart with undifferentiated iPS cells4.
However, concerns about the maturity and functional heterogeneity of stem cell-derived
cardiomyocytes,5 the low survival and retention of delivered cells, as well as their potential
tumorigenicity still exist6, 7. Some of these limitations could be overcome by direct
reprogramming of somatic cells into cardiomyocytes obviating an intermediate pluripotent
stage. Indeed, a recent report from Srivastava’s group describes the use of three cardiac
transcription factors (Gata4, Mef2c and Tbx5) to reprogram mouse fibroblasts directly into
cardiomyocytes8. Importantly, there is no evidence reported as yet, for direct
reprogramming in vivo.
A promising alternative strategy for direct reprogramming is the use of microRNAs
(miRNAs)9. The repressive actions of miRNAs on gene expression can be powerful as a
single miRNA may target multiple pathways simultaneously. Chemically synthesized
miRNA mimics are easily administered to cells via lipid-based transfection and exhibit low
toxicity in animal models10. Moreover, the small size of a single miRNA allows the packing
of multiple transcripts in the same delivery vector to increase both reprogramming
efficiency and functional homogeneity of reprogrammed cells11.
In this report, we present the first evidence of miRNA-mediated direct conversion of
fibroblasts to the cardiomyocyte lineage, in vitro and in vivo. Indeed, our data show that
mouse fibroblasts can be directly converted to a cardiomyocyte-like phenotype in vitro by a
single transient transfection using a distinct combination of miRNAs (miRNAs 1, 133, 208,
and 499), enhanced further by JAK inhibitor I treatment. Reprogrammed cells express
cardiomyocyte-specific genes and proteins and additionally, exhibit sarcomeric
organization, spontaneous calcium oscillations and mechanical contractions characteristic of
a cardiomyocyte-like phenotype. Importantly, studies using genetically-traced fibroblasts
also suggest that such conversion can be achieved directly in the injured myocardium
following miRNA delivery. Our work provides the first insight into the role miRNAs may
play in cardiac reprogramming biology as well as a novel and potentially more efficient
method of achieving cardiomyocyte regeneration in situ.
METHODS
miRNA, transfections, qRT-PCR
Synthetic mimics of mature microRNAs (Ambion/Applied Biosystems) were introduced
into cells via transient transfection with Dharmafect1 (ThermoScientific) using standard
conditions and at a final concentration of 50nM. As a negative control, we used a random
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sequence non-targeting mimic (negmiR) miRNA (Ambion/Applied Biosystems). Total RNA
was isolated using RNeasy-96 (Qiagen) and PicoPure RNA isolation kits (Applied
Biosystems). JAK inhibitor I (EMD Biosciences) treatment (final concentration 1nM) was
initiated 2 days following transfection and continued daily for 5–8 days. Quantitative
expression of each gene was assessed using Taqman Gene Expression Assays on the
StepOnePlus Real-Time PCR System (Applied Biosystems).
Immunocytochemistry, Microscopy and FACS
Cells were fixed in 4% paraformaldehyde and stained using the following primary
antibodies: α-actinin (Sigma), myosin heavy chain (Developmental Studies Hybridoma
Bank, & Abcam), cardiac troponin I and T (Abcam), CD45 (BD Biosciences), Ckit (R&D),
Smooth muscle actin (Sigma), Vimentin (Abcam), Ddr2 (R&D), RFP (Rockland
Immunochemicals). Confocal images were captured using an LSM 510 Meta DuoScan
microscope (Zeiss) and processed using LSM 5 software, version 4.2. Images of CFP
expression were captured using the AxioObserver widefield fluorescence microscope
(Zeiss). 3D images were reconstructed using Imaris software (Bitplane) of 20X confocal
images using the microscope mentioned above. FACS sorting was performed using a
FACStar Plus cytometer (BD Biosciences). All FACS samples were gated against an
untransfected cell control 7–10 days post-transfection with miRNAs. The CFP+ cell
population generated by FACS was first tested for the presence of Myh6 (since CFP is
driven by the αMHC promoter) using qRT-PCR before evaluating for the expression of
other genes.
Calcium Imaging and Contractility
Ca2+ signals in cardiac fibroblasts and myocytes were imaged using Fura-2 according to
previously published protocols 12, 13. (Please see SI for additional methods).
In vivo Studies
Adult, male Fsp1Cre-tdTOMATO transgenic mice were subjected to LAD using previously
published procedures 14. Lentiviral microRNAs (2×106 pfu in 40μL) were injected once at
the time of injury, at two sites 2mm below site of ligation. Animals were harvested after 4
weeks, fixed, paraffin-embedded, and stained with anti-RFP (Rockland Immunochemicals)
and anti-cardiac troponin T (Abcam).
RESULTS
Based on the potential miRNAs hold for regulating cellular and developmental
processes15–18, we hypothesized that they may be capable of redirecting cardiac cell fate. In
this study, we developed a strategy to identify specific miRNAs capable of reprogramming
cardiac fibroblasts directly to the cardiomyocyte lineage. We selected six candidate miRNAs
based on their roles in cardiac muscle development and differentiation19–24. Synthetic,
chemically-modified mimics of miRNAs 1; 126-3p (126); 133a (133); 138, 206; and
208a(208) were introduced into mouse cardiac fibroblasts via transient transfection, alone
and in all possible double and triple combinations with each other, resulting in a total of 41
different compositions (Figure 1a). These were initially evaluated for their reprogramming
potential by screening for induction of markers of cardiac differentiation in MEFs, neonatal
and adult cardiac fibroblasts at 3 and 6 days post-transfection using quantitative real-time
PCR (qRT-PCR) (Figure 1a-c and Online Figure II). Markers included previously
characterized cardiac reprogramming markers8 Gata4, Mef2c, Tbx5, as well as later stage
mature cardiomyocytes markers such as Tnni3 (Cardiac troponin I). To ensure that our
starting population of cardiac fibroblasts was not contaminated with cardiomyocytes, we
subjected our preps to Percoll gradient centrifugation to remove the cardiomyocyte fraction
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and further, confirmed by FACS analysis, that contamination by cardiomyocytes or c-Kit+/
sca-1+ progenitor cells is insignificant (0.01–0.04%, data not shown).
Our results showed that as early as 3 days post-transfection, miRNA-transfected cells
exhibited a major shift in expression from fibroblastic genes such as Vimentin (Vim) and
Ddr2 to cardiomyocyte-specific genes (Figure 1a). Additionally, controls (non-targeting
miRNA (negmiR), mock and untransfected cells) including the transfection of fibroblast-
enriched miR-21 did not activate cardiomyocyte markers. Interestingly, gene expression
data were clustered into defined groups where distinct miRNA compositions appeared to
regulate the expression of stage-specific markers of cardiac differentiation. This approach
identified miRNA combinations that consistently induced a fibroblastic-myocyte phenotypic
shift in both neonatal and adult cardiac fibroblasts (Figure 1a-c). Top candidates identified
included miR-1 alone; miRs-1, 133, 206; miRs-1, 133, 208; miRs-133, 206, 208; miR-1,
138, and miRs-1, 138, 208.
To further validate these findings, we performed immunostaining on miRNA-transfected
neonatal and adult cardiac fibroblasts for induced cardiomyocyte-specific markers including,
myosin heavy chain (MHC), Cardiac troponin I (TNNI3), and α –ACTININ. As shown in
Figure 1d & e and Online Figures III & IV, immunostaining on adult and neonatal cardiac
fibroblasts revealed that top miRNA candidates induced protein expression of MHC, TNNI3
and/or α-ACTININ as early as 6 days after transfection. Complementary experiments
conducted using fibroblasts isolated from transgenic mice expressing α-myosin heavy
chain-driven cyan fluorescent protein (αMHC-CFP) revealed that αMHC was activated as
early as 4 days post-transfection (Online Figure V). Moreover, transient transfection of
neonatal cardiac fibroblasts isolated from double transgenic mice carrying both the
Fibroblast-specific promoter 1 (Fsp1)-driven Cre recombinase gene25 and a floxed tdTomato
reporter26(Fsp1-Cre/tdTomato) with miRNAs resulted in co-localization of the tdTomato
marker with cardiac markers TNNI3 or α-ACTININ (Figure 1f and Online Figure VI),
providing strong evidence for the fibroblastic origin of miRNA-induced cardiomyocyte-like
cells. No expression of TNNI3 or α-ACTININ was detected in the any of the control
fibroblasts (Online Figure VII). Interestingly, as shown in Figure 1e, prominent striations
were observed as early as 1 week post-transfection in TNNI3+ cells. Organization and
definition of TNNI3 and α-ACTININ expression increased progressively between 2 and 4
weeks following miRNA introduction (Figure 1f and Online Figure VI). To further test the
levels of cardiac markers in reprogrammed cells specifically, we sorted the CFP+ population
from αMHC-CFP neonatal cardiac fibroblasts by FACS 1 week following miRNA
transfection. We chose to focus on miR-1 alone and the combination miRs-1, 133, 208 due
to their overall potential at cell conversion and cardiac specificity. Interestingly, inclusion of
myosin-regulated miR-49927 in the miRNA combination 1, 133, 208 did not change
reprogramming efficiency as measured by CFP expression (Figure 2a). However, it did
seem to increase the levels of cardiomyocyte marker expression (Figure 2b). Indeed,
quantitative real-time PCR analysis of the CFP+ selected cells from fibroblasts transfected
with miRs-1, 133, 208, 499 revealed a significant increase in expression of the cardiac
developmental marker Mef2c, and that of the late-stage marker, Tnni3. Overall the above
results provide strong evidence for the capacity of miRNAs to induce expression of
cardiomyocyte markers in cardiac fibroblasts.
The data thus far have demonstrated that miRNAs are capable of inducing cardiomyocyte
marker expression in fibroblasts albeit at low efficiency. Since it has been reported that
small molecules might enhance cell conversion/differentiation, we decided to investigate
their effects on miRNA-induced cardiac reprogramming17, 28, 29. Interestingly Efe and
colleagues3 subjected partially reprogrammed mouse embryonic fibroblasts with sequential
addition of JAK inhibitor I and BMP4 treatment to activate the cardiac progenitor program
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which yielded beating cardiomyocytes within three weeks. To evaluate the potential of this
approach neonatal cardiac fibroblasts from αMHC-CFP mice were treated with miRNAs
and JAK inhibitor I. Cells were assayed by FACS for enhancement of a CFP+ cell
population over transfection with miRNAs alone. Transfection with these miRNA
compositions resulted in induction of CFP expression in approximately 1.5–7.7% of
fibroblasts (Figure 2a). However, additional treatment with JAK inhibitor I dramatically
shifted the profile of CFP+ cells (up to ~28% of CFP+ cells) and increasing the efficiency of
reprogramming approximately 8–10 fold (Figure 2a & c). None of the other compounds
tested seemed to enhance miRNA-induced reprogramming efficiency (data not shown).
Remarkably, the combination of miRs-1,133, 208, 499 plus JAK inhibitor I treatment also
led to a significant elevation of ion channel expression in CFP+ cells resulting in an almost
10-fold increase in expression of the L-type calcium channel Cacna1c, when compared to
non-JAK inhibitor I-treated miRNA-transfected cardiac fibroblasts (Figure 2d and Online
Figure VIII).
To further validate the functional consequences of the above observations, we analyzed
calcium signaling, excitation-contraction (EC) coupling and spontaneous contraction. CFP+
cells were treated with miRNA combinations versus control, all in the presence of JAK
inhibitor I, for up to 4 weeks post-FACS (Figure 3). Spontaneous contraction was observed
as early as 10 days in culture however this was sporadic (1–2% of total cell population).
Rhythmic calcium oscillations were also often observed in miRNA transfected cells by 14
days post-FACS, but only rarely observed in control cells (negmiR and untransfected
fibroblasts). Both the incidence and oscillation frequency of spontaneous calcium
oscillations in miRNA-transfected fibroblasts increased with time in culture (not shown),
suggesting an increase in the state of maturation. The average oscillation frequencies were
significantly faster in CFP+ cells derived from fibroblasts transfected with miR-1 and
miRs-1, 133, 208, 499 (1.31±0.31 oscillations/min; range: 0.15–4 oscillations/min and
1.54±0.14 oscillations/min; range: 0.1–3.15 oscillations/min, respectively) than in controls
(0.45 and 0.6 oscillations/min), and reached about 50% of the average frequency observed in
cultured neonatal cardiomyocytes (2.93±0.13 oscillations/min; range: 1–12 oscillations/min)
(Figure 3a and b). There was also a substantial increase in the number of cells exhibiting
oscillations in CFP+ reprogrammed cells (Figure 3c). Moreover, both the average oscillation
frequency and the number of oscillating cells detected were greater in CFP+ cells derived
from miR-1, 133, 208, 499-transfected fibroblasts than those transfected with miR-1 alone
(Figure 3b and c), suggesting that the combination of miRNAs was more effective than
miR-1 alone. To assess calcium entry through voltage-gated calcium channels, we also
measured responses to membrane depolarization (Figure 3d). Consistent with the increased
expression of the L-type calcium channels in CFP+ cells, depolarization with high
extracellular [K+] (60 mM) produced a calcium transient or induced the onset of oscillations
in CFP+ cells (Figure 2d, 3d and Online Figure VII), whereas control cells rarely exhibited a
calcium response (Figure 3e). This suggests that miRNA-transfected fibroblasts develop the
cellular machinery of EC coupling, a hallmark of functional cardiomyocytes. Together,
these findings provide functional support for reprogramming of miRNA-transfected
fibroblasts towards a cardiomyocyte phenotype, albeit less fully matured, as evidenced by
the presence of spontaneous calcium oscillations and EC coupling, and further suggest that
calcium entry through voltage-gated calcium channels plays a role in regulating calcium
oscillations in these cells.
Additionally, to explore the route of cardiac reprogramming, we assessed for expression of
the pluripotency markers Oct4 and Nanog immediately following miRNA introduction, at
24 hour intervals, till the induction of cardiomyocte marker expression in both neonatal and
adult cells and did not observe any change in gene expression relative to experimental
controls (data not shown). However, we did observe rapid induction of primitive cardiac
Jayawardena et al. Page 5













mesodermal marker Mesp2 as early as 1 day post-transfection in the case of miRs-1, 133,
208, 499 and by day 5 in the case of miR-1 (Online Figure IX). These data, along with an
observed reduction in fibroblastic markers Ddr2 and Vim (Online Figure X) suggest that
reprogramming events taking place in the fibroblasts are the result of a direct switch in cell
fate circumventing passage through a pluripotent precursor cell type.
To evaluate the potential of our approach in the adult heart, we injected lentivirus encoding
miR-1 or a combination of four lentiviruses encoding the miR combo (miRs-1, 133, 208,
499). A lentivirus encoding a non-targeting miRNA (negmiR) was used as a negative
control. Viruses were injected intramyocardially immediately following injury by permanent
ligation of the left ascending coronary artery (2 injection sites 2 mm below ligation site).
The recipient double transgenic Fsp1-Cre/tdTomato mice allowed us to genetically-trace the
fate of endogenous cardiac fibroblasts in vivo and investigate whether they were
reprogrammed to a cardiac phenotype. Four weeks after infarction and virus injection, hearts
were harvested, fixed and stained for cardiac troponin T (TNNT2) and tdTomato expression
(Figure 4a and b and Online Figure XI). Analysis of the infarct areas in the left ventricular
myocardium of mice injected with either miR-1 or the miR combo revealed the presence of
large, striated, double-positive cells (tdTomato+/TNNT2+) well-incorporated in the
surrounding cardiac syncytium. These were not observed in negmiR-injected hearts (Online
Figure XIV). Co-expression of tdTomato and TNNT2 was further substantiated following
3D re-construction of confocal images (Figure 4b). Moreover, cardiomyocytes were isolated
6 weeks following permanent ligation of αMHC-CFP/Fsp1-Cre/tdTomato mice that had
been injected with either the miR combo or negmiR (at the time of injury). The number of
CFP+/tdTomato+ cardiomyocytes was then quantified; approximately 1% of
cardiomyocytes from an infarcted heart injected with the miR combo were double positive
for CFP and tdTomato whereas only one double-positive cardiomyocyte was found from a
negmiR-injected heart (Figure 4c). The background fluorescence of tdTOMATO in the CFP
channel and vice-versa was also examined and is provided in Online Figures XII and XIII).
As shown, no background signal or overlap was detected in either the dtTomato or the CFP
channels.
Although Fsp1-Cre is predominantly expressed in fibroblasts, activation in other cell types is
a possibility. To address this we did extensive studies using both immunocytochemistry and
FACS analysis to determine co-expression of the tdTomato marker with markers for
cardiomyocytes, cardiac stem cells, inflammatory and vascular cells in the injured heart but
we did not observe co-expression with the above-mentioned cell types (Online Figures IV-
VI). To further provide evidence and exclude the possibility of our observations being the
result of cardiac differentiation from progenitor cells rather than the reprogramming of
fibroblasts, we tested for the capacity of miRs-1, 133, 208, 499 to induce cardiac
reprogramming in fibroblasts of extra-cardiac origin. As shown in Figure 4d and Online
Figures XVII-XIX, the combination of miRs-1, 133, 208, 499 was capable of mediating
cardiomyocyte induction in adult tail tip fibroblasts. As with neonatal cardiac fibroblasts, we
also observed a significant elevation of %CFP induction with JAK inhibitor I treatment in
reprogrammed adult tail tip fibroblasts (Online Figures XVIII and XIX). We did find,
however, that cells reprogrammed from adult tail tip fibroblasts were at a less mature stage
in their cardiac phenotype when compared with reprogrammed counterparts from neonatal
cardiac fibroblasts (no spontaneous contraction was observed). Significantly, the use of adult
fibroblasts isolated from the tails of αMHC-CFP/Fsp1Cre/tdTOMATO mice (Figure 4d)
further strengthens our observation that induced cells do not originate from contaminating
cardiac progenitors. Additionally, the induction of cardiomyocyte-like cells in adult tail tip
fibroblasts strongly implies that reprogramming is not due to cell fusion between fibroblasts
and cells of a cardiac lineage but is in fact consequential to cellular reprogramming.
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In summary, we provide the first evidence that distinct miRNAs are capable of inducing
conversion of fibroblasts to cardiomyocyte-like cells. Moreover, this is the first report of
cardiac direct reprogramming (in this case using miRNA) in vivo, and serves as proof of
concept that this distinctive, innovative approach can be used to switch cell fate and induce
regeneration in the heart (obviating the use of cell transplantation methods used heretofore).
Remarkably, our studies suggest that miR-1 alone is sufficient to induce cardiac
reprogramming but its effects are dramatically enhanced in combination with miRNAs 133,
208, and 499 and even further with JAK inhibitor I treatment. Indeed, our analysis revealed
a specific set of miRNAs (miR-1, mir 133, mir 208 and mir 499) that was efficient not only
at inducing expression of cardiac markers in fibroblasts but also efficient at converting the
fibroblasts into cells with functional properties characteristic of cardiomyocytes such as L
type channel expression, spontaneous calcium oscillations and contractility. Interestingly,
the full combination of miRNAs did not change the total number of reprogrammed cells (as
measured by % CFP+ cells) but rather enhanced the maturation of converted cells.
Moreover, the effectiveness of partnering miRNAs with JAK inhibitor I treatment led to a
significant increase in efficiency via enhancement of both αMHC induction and expression
of cardiac ion channels. While the exact molecular pathways involved in these processes
remain unresolved for now, our initial studies suggest that the miRNAs directly convert
fibroblasts to cells of the cardiomyocyte lineage without intermediate conversion to a
pluripotent state. In addition, the exact mechanism of JAK inhibitor I remains unclear.
Recently, JAK inhibitor I has been reported to promote cardiomyocyte transdifferentiation
of partially reprogrammed embryonic fibroblasts via suppression of pluripotency-promoting
pathways3. Whether its effects are similar in postnatal cardiac fibroblasts remains to be
investigated. Indeed, this is the first report describing a significant increase in efficiency of
miRNA-induced direct cardiac reprogramming using this particular small molecule and may
represent a major advancement in this arena.
Importantly we provide the first evidence of a non-viral method at accomplishing efficient
miRNA-mediated direct cellular reprogramming of one somatic cell to another in vitro. This
alone suggests that continual upregulation of miRNAs is not necessary for reprogramming
to occur and that a single transient transfection of miRNAs is sufficient for cell fate
switching suggesting further that the latter may actually take place within the first days of
miRNA introduction. Remarkably, we provide the first evidence that distinct miRNAs are
capable of inducing direct conversion of nonmyocytes to cardiomyocyte like cells in vivo.
Moreover, genetic tracing methods suggest that induced cardiomyocyte-like cells are most
likely of fibroblastic origin. We acknowledge that the use of Fsp1Cre might not serve as the
ideal model for genetic tracing of cardiac fibroblasts. However, our preliminary data
suggesting that Fsp1 is not expressed in non-fibroblasts (i.e. stem cells, smooth muscle cells,
inflammatory cells) in the injured myocardium as well as evidence of reprogramming in
adult tail tip fibroblasts provides multiple lines of support for the occurrence of fibroblast
reprogramming in the injured myocardium. Interestingly, dermal fibroblasts transfected with
miRNAs, despite the presence of clear upregulation of cardiomyocyte markers, rarely
exhibited induced calcium transients indicating that the reprogrammed phenotype is at a less
mature stage when compared with cardiac fibroblasts as the originating cell. This is in line
with the experience of others in the reprogramming field who have also acknowledged
challenges with reprogramming/driving tail tip fibroblasts to a functionally responsive
cardiomyocyte-like phenotype8. Whether the propensity of those cells to become
cardiomyocytes is correlated with their developmental origins remains to be determined.
Importantly, our work also serves as proof-of-concept that it is possible to inject miRNAs
directly in vivo, and achieve fibroblastic conversion to cardiomyocytes in the scar and peri-
infarct areas of the heart. Significantly, these events were a result of the actions of miRNAs
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alone suggesting that the efficiency of reprogramming may be elevated in vivo by the
dynamic cross-talk present within the microenvironment of a complex tissue versus the two-
dimensional cell culture dish. Further optimization of miRNA delivery methods combined
with JAK inhibitor I treatment in vivo may amplify the therapeutic implications of our work.
Collectively, this study presents the first evidence of miRNA-induced direct conversion to
cardiomyocytes in vitro and in vivo and demonstrates the powerful effect of this group of
small RNAs at mediating cellular reprogramming.
Supplementary Material
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iPS Induced pluripotent stem cell
αMHC-CFP alpha myosin heavy chain-driven cyan fluorescent protein
tdTOMATO tandem dimer TOMATO (fluorescent protein)
Fsp1 Fibroblast-specific protein 1
TNNI3 Troponin I, type 3 (cardiac)
TNNT2 Troponin T, type 2 (cardiac)
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• Cardiac injury is characterized by inadequate regeneration and excessive
fibrosis.
• Cellular reprogramming could potentially be used for cardiac regenerative
therapy.
• Cardiac fibroblasts represent therapeutic targets for in vivo reprogramming into
cardiomyocytes.
• A promising strategy for direct reprogramming is the use of microRNAs
(miRNA).
What New Information Does This Article Contribute?
• Distinct miRNAs are capable of converting fibroblasts to cardiomyocytes-like
cells in vitro.
• JAK inhibitor I treatment enhances miRNA-mediated reprogramming to
cardiomyocytes
• Cardiac fibroblasts could be reprogrammed to cardiomyocytes
• In vivo reprogramming of fibroblasts in the heart using miRNAs, may yield a
more straightforward method for cardiac regeneration.
Response to cardiac injury is usually characterized by inadequate regeneration and
excessive fibrosis resulting in significant impairment of tissue structure and function.
Although stem cell therapy holds promise, the data thus far suggest that authentic cardiac
regeneration is modest at best. Recently, reports of reprogramming of somatic cells to
inducible pluripotent stem cells or cells of other lineages have raised the possibility of
using reprogrammed cells for cell therapy.. A method to directly convert the injured areas
to functional tissue in vivo would be the ideal. Here, using a model of cardiac injury, we
provide the first evidence that fibroblasts can be directly reprogrammed to
cardiomyocytes in the heart. Our studies show that a) miRNAs are capable of converting
fibroblasts to cardiomyocyte-like cells in vitro. b) miRNAs can direct in vivo conversion
of fibroblasts to cardiomyocytes in the adult mouse myocardium and c) a combination of
miRNAs with JAK inhibitor I treatment, significantly increases the efficiency of
fibroblast reprogramming towards the cardiac fate. A therapeutic approach administering
miRNAs would represent a novel and potentially simpler strategy to stimulate cardiac
regeneration. This approach may have broad implications for therapeutic tissue
regeneration in general.
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Figure 1. Introduction of microRNA(s) into cardiac fibroblasts induces the expression of cardiac
myocyte-specific markers
a, Cumulative gene expression data from miRNA-transfected adult cardiac fibroblasts are
illustrated graphically in heat map form. These results depict a major shift in fibroblastic
(Ddr2 & Vim) to early cardiomyocyte (Isl1, Nkx2.5, Gata4, Hand2, Mef2c, and late cardiac
myocyte (Tnni3, Cx43) marker expression between 3 and 6 days post-transfection. Fold
change in normalized gene expression for each gene is shown on a green to black to red
scale (Minimum(Green) – Maximum(Red). Detailed color legends describing quantitative
fold change data for each gene are represented in Online Figure XX. b, Representative bar
graphs showing RNA expression profiles of Gata4 and Mef2c in neonatal cardiac fibroblasts
at 3 days post-transfection. Highlighted are top miRNA combinations 1, 133, 206 and 1,
133, 208. All miRNA combinations represented by light grey bars. Dark grey bar represents
averaged controls; untransfected, mock and non-targeting miRNA (negmiR). Results
presented as mean ± SEM. c, Representative scatter plot showing the geometric mean of
normalized expression of Gata4, Mef2c, and Tbx5 at 3 days post-transfection. Highlighted
are: miRs-1, 133, 208 (red); and miRs-1, 133, 206, (purple); mock, negmiR, and
untransfected controls (green); remaining miRNA combinations (black). d, α-ACTININ (in
green) immunostaining of DAPI-postive (blue) neonatal cardiac fibroblasts 1 week
following transfection with miR-1; miRs-1, 133, 206; miRs-1, 133, 208; and miRs-133, 206,
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208. Scale bar, 100μm. e, TNNI3 (in green) immunostaining of DAPI-positive (blue)
neonatal cardiac fibroblasts 1 week following transfection with miRs-1, 133, 208. Zoomed
in area highlights the presence of prominent striations in TNNI3+ cells. f, TNNI3 (in green)
immunostaining of DAPI-postive (blue) neonatal cardiac fibroblasts isolated from Fsp1Cre/
tdTOMATO (red) mice, 4 weeks following transfection with miRs-1, 138, 208. Scale bar,
100μm.
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Figure 2. Cardiac induction is enhanced by the addition of miR-499 and /or small molecule
inhibitor of JAK Inhibitor I
a, Summary from FACS analyses data of miRNA-transfected neonatal cardiac fibroblasts.
Cardiac fibroblasts were isolated from αMHC-CFP neonatal transgenic mice and induced
CFP+ population was analyzed and sorted by FACS 7 days after transfection. In samples
involving JAK inhibitor I treatment, miRNA-transfected cells were treated with the small
molecule 48 hours post-transfection and then sorted by FACS. Provided is the range of
%CFP induction for each miRNA combination +/− JAK inhibitor I for several experimental
rounds (n=4–8). b, RNA expression of cardiac myocyte-specific markers Mef2c, Tnni3, and
Myh6 in CFP+ cells sorted from neonatal cardiac fibroblasts 1 week following transfection
with miR-1 and miRs-1, 133, 208, 499. c, Representative FACS analyses demonstrating the
induction of αMHC-driven-CFP+ cell population in miRNA-transfected neonatal cardiac
fibroblasts with and without treatment of JAK inhibitor I, 1 week post-transfection. FACS
traces are distinguished as follows: untransfected cells (green), negmiR-transfected cells
(red) and miRNA-transfected cells (light blue). For b, results presented as mean ± SEM. *
P<0.05, one way ANOVA with Bonferroni correction. Stated p value is versus non-targeting
miRNA control. d, RNA expression levels of cardiac ion channels, Cacna1c, Scn5a, and
Kcnj2, in CFP+ cells sorted from JAK inhibitor I-treated neonatal cardiac fibroblasts, 1
week following transfection with miR-1 and miRs-1, 133, 208, 499. Both untransfected and
negmiR controls were also treated with the JAK inhibitor I. For f, results are presented as
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mean ± SEM. * P<0.05, one way ANOVA with Bonferroni correction. Stated p value is
versus negmiR control.
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Figure 3. miRNA-transfected cardiac fibroblasts exhibit spontaneous calcium oscillations and
calcium transients in response to depolarization
a, Representative examples of spontaneous calcium oscillations in CFP+ cells 14 days post-
FACS from JAK inhibitor I-treated cardiac fibroblasts transfected with miRNAs, or negmir
and in neonatal cardiac myocytes. b, Average oscillation frequencies in miR-1 (n=17) and
miR-1, 133, 208, 499 (n=40) transfected cardiac fibroblasts at 14 days post-FACS. Controls
are untransfected (n=1) and negmir-transfected (n=1) cardiac fibroblasts and neonatal
cardiomyocytes (n=88). All miRNA-transfected and control cardiac fibroblasts were
subjected to JAK inhibitor I treatment. c, Total number of oscillating cells in miRNA-
induced, JAK inhibitor I-treated CFP+ and control cell populations at 14 days post-FACS
(expressed as a percentage of the number observed in miR-1, 133, 208, 499-induced CFP+
population). d, Representative example of a calcium response to depolarization with high
[K+] (60 mM) in miR-1-induced CFP+ cells at 14 days post-FACS. High [K+] (2 min
exposure) induced the onset of calcium oscillations that persisted following reintroduction of
low [K+] Ringer. e, Percentage of miR-1 (n=19), miR-1, 133, 208, 499 (n=13), and negmir
(n=11) transfected and untransfected (n=16) cardiac fibroblasts that exhibited a calcium
response to depolarization with high [K+]. These data were collected from two independent
experimental rounds, with at least 8 fields of cells sampled from each. All miRNA-
transfected and control cells were subjected to JAK inhibitor I treatment.
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Figure 4. MicroRNA-injected endogenous cardiac fibroblasts are reprogrammed in vivo
following myocardial injury
a, Fsp1Cre/tdTOMATO transgenic mice were injected with miRNAs intramyocardially at
the time of permanent ligation of the left ascending coronary artery (LAD). Four weeks
later, hearts were harvested, fixed, and immunostained with antibodies against tdTOMATO
(red) and cardiac troponin T (TNNT2) (green). Nuclear staining with DAPI(blue). For split
channel images, please refer to Online Figure XI. Large, double-positive cells (red and
green) with prominent striations (highlighted with arrows), often organized as part of
clusters, were taken as evidence of reprogrammed cardiac fibroblasts. Shown here are
representative images from infarct and peri-infarct areas of miR-1 and miRs-1, 133, 208,
499-(miR combo) injected hearts. Scale bar, 100 μm. Zoomed in area highlights a
representative example of the presence of prominent striations in tdTOMATO+ TNNT2+
cells from miRNA-injected hearts. b, Zoom of selected confocal microscopy image from the
heart of a miRNA-injected heart from a Fsp1Cre-tdTOMATO animal; orthogonal slide of
3D reconstructed 20X confocal image using Imaris software. Maximum intensity projection
of images to allow visualization of co-expression of fluoresence signals tdTOMATO (red),
and TNNT2 (green) and red and green co-expression (yellow) to ensure that the observed
co-localization is not due to cell staggering. 20X magnification of selected areas in the
different planes X-Y, X-Z, and Y-Z. Panels show merged signal (yellow) in all the different
planes. Scale bar, 20 μm. c, αMHC-CFP/Fsp1-Cre/tdTOMATO transgenic mice were
injected with either miR combo or negmiR following permanent ligation. Six weeks later,
Jayawardena et al. Page 17













cardiomyocytes were isolated and CFP+/tdTOMATO+ cells quantified. Shown is a
representative example of a double positive cardiomyocyte isolated from a miR combo-
injected animal. Individual panels for CFP and tdTOMATO are shown as well as a merged
overlay of both channels. For background fluorescence of tdTOMATO and CFP channels,
please refer to Online Figures XII and XIII. d, Representative live cell images of αMHC-
driven-CFP and Fsp1Cre-driven tdTOMATO expression in adult tail tip fibroblasts (ttf) 3
weeks following transfection with miR combo. Live cell images are merged displays that
constitute CFP (in green), tdTOMATO (in red) and Hoechst (in blue). Scale bar, 50 μm. For
split channel images, please refer to Online Figure XVII. NegmiR-treated control is shown
as a representative of all controls used including untransfected and mock controls.
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